A Phase 1/2 interventional study of Matching placebo and Cenerimod in Systemic Lupus Erythematosus, sponsored by Viatris Innovation GmbH. Completed at 18 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Lupus Erythematosus, Systemic with a site in Russia — none open to participants now, 3 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · Russia.
Among the 12 studies in Lupus Erythematosus, Systemic with a site in Russia, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2015, is one of 2 in phase 1/2, and was the 3rd registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →None of the 12 studies in Lupus Erythematosus, Systemic with a site in Russia is open now. The open studies under Lupus Erythematosus, Systemic, anywhere →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 3 · Phase 4 1
First in 2012; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 261 across the 11 interventional studies, 637 across the 1 observational. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 8 most frequent:
This study is registered under Viatris Innovation GmbH, one of the names counted as Viatris Inc.. Under that name alone:
Viatris Innovation GmbH is the lead sponsor of 24 studies on the registry; 3 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
Viatris Inc. has 7 studies filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
1 of the studies in Lupus Erythematosus, Systemic with a site in Russia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Lupus Erythematosus, Systemic with a site in Russia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
International trial to evaluate the biological activity and safety of cenerimod (ACT-334441) in systemic lupus erythematosus (SLE) patients.
This multicentre, double-blind, placebo-controlled study will have a staggered approach (Part A and B).
In part A, eligible patients will be randomly assigned (1:1:1:1) to once daily oral administration of cenerimod (0.5, 1, 2 mg) or placebo. After all patients have completed 4 weeks of treatment during part A, an Independent Data Monitoring Committee will review non-blinded data in an interim analysis to evaluate the safety profile of cenerimod and recommend whether the study could proceed to part B.
In part B, additional patients will be randomized (3:1) to once daily oral administration of cenerimod 4 mg or placebo.
All participants will receive study medication for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive cenerimod 0.5 mg capsules orally once daily for 12 weeks.
Drug: Cenerimod
Participants will receive cenerimod 1 mg capsules orally once daily for 12 weeks.
Drug: Cenerimod
Participants will receive cenerimod 2 mg capsules orally once daily for 12 weeks.
Drug: Cenerimod
Participants will received cenerimod 4 mg capsules orally once daily for 12 weeks. This treatment arm will start after all patients in Part A have completed 4 weeks of placebo, 0.5 mg, 1 mg and 2 mg cenerimod treatment.
Drug: Cenerimod
Capsules of matching placebo taken orally once daily for 12 weeks.
Drug: Matching placebo
One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
Also known as: Placebo
One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
Also known as: ACT-334441
Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT)
The primary objective of the clinical study was to asses whether cenerimod could reduce the number of circulating lymphocytes in the bloodstream of people with systemic lupus erythematosus (SLE). The change was defined as: Total lymphocyte count at end-of-treatment (EOT) minus total lymphocyte count at baseline. A negative change over time indicates that the number of peripheral circulating lymphocytes has decreased. The reduction of the total lymphocyte count over a treatment period indicates a pharmacodynamic effect. The value at baseline was defined as the last non-missing value obtained from a sample taken prior to the first study treatment intake. End-of-treatment (EOT) was defined as the last post-baseline value with treatment for at least 21 days up to Week 12.
Time frame: Baseline to end-of-treatment (EOT) (up to 12 weeks)
Change in Total Lymphocyte Count From Baseline to Each Post-baseline Assessment
The primary objective of the clinical study was to assess whether cenerimod could reduce the number of circulating lymphocytes in the bloodstream of people with systemic lupus erythematosus (SLE). The change was defined as: Total lymphocyte count at visit minus total lymphocyte count at baseline. A negative change over time indicates that the number of peripheral circulating lymphocytes has decreased. The reduction of the total lymphocyte count over a treatment period indicates a pharmacodynamic effect. The value at baseline was defined as the last non-missing value obtained from a sample taken prior to the first study treatment intake. End-of-treatment (EOT) was defined as the last post-baseline value with treatment for at least 21 days up to Week 12.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, end-of-treatment Visit (up to 12 weeks)
This study was conducted at 18 sites in 6 countries between 1 June 2015 and 28 February 2017, 105 patients signed consent and 67 were randomized to a study treatment: 49 in part A (randomized 1:1:1:1 to receive cenerimod 0.5, 1, 2 mg or placebo) and 18 in part B (randomized 3:1 to receive cenerimod 4 mg or placebo).
| Milestone | Cenerimod 0.5 mg (Part A) | Cenerimod 1 mg (Part A) | Cenerimod 2 mg (Part A) | Cenerimod 4 mg (Part B) | Matching Placebo (Part A and B) |
|---|---|---|---|---|---|
| Started | 12 | 12 | 13 | 13 | 17 |
| Pharmacodynamic set | 12 | 10 | 13 | 13 | 16 |
| Modified pharmacodynamic analysis set | 12 | 10 | 13 | 9 | 16 |
| Completed | 12 | 11 | 13 | 13 | 14 |
| Not completed | 0 | 1 | 0 | 0 | 3 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 |
The primary objective of the clinical study was to asses whether cenerimod could reduce the number of circulating lymphocytes in the bloodstream of people with systemic lupus erythematosus (SLE). The change was defined as: Total lymphocyte count at end-of-treatment (EOT) minus total lymphocyte count at baseline. A negative change over time indicates that the number of peripheral circulating lymphocytes has decreased. The reduction of the total lymphocyte count over a treatment period indicates a pharmacodynamic effect. The value at baseline was defined as the last non-missing value obtained from a sample taken prior to the first study treatment intake. End-of-treatment (EOT) was defined as the last post-baseline value with treatment for at least 21 days up to Week 12.
| 10^9 cells/L | Cenerimod 0.5 mg (Part A) | Cenerimod 1 mg (Part A) | Cenerimod 2 mg (Part A) | Cenerimod 4 mg (Part B) | Matching Placebo |
|---|---|---|---|---|---|
| Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT) | -0.26 ± 0.48 | -0.96 ± 0.68 | -0.86 ± 0.61 | -0.87 ± 1.24 | -0.33 ± 0.72 |
The primary objective of the clinical study was to assess whether cenerimod could reduce the number of circulating lymphocytes in the bloodstream of people with systemic lupus erythematosus (SLE). The change was defined as: Total lymphocyte count at visit minus total lymphocyte count at baseline. A negative change over time indicates that the number of peripheral circulating lymphocytes has decreased. The reduction of the total lymphocyte count over a treatment period indicates a pharmacodynamic effect. The value at baseline was defined as the last non-missing value obtained from a sample taken prior to the first study treatment intake. End-of-treatment (EOT) was defined as the last post-baseline value with treatment for at least 21 days up to Week 12.
| 10^9 cells/L | Cenerimod 0.5 mg (Part A) | Cenerimod 1 mg (Part A) | Cenerimod 2 mg (Part A) | Cenerimod 4 mg (Part B) | Matching Placebo |
|---|---|---|---|---|---|
| Baseline visit | 1.37 ± 0.52 | 1.71 ± 0.82 | 1.62 ± 0.75 | 1.88 ± 0.77 | 1.65 ± 0.88 |
| Week 2 visit | -0.13 ± 0.56 | -0.48 ± 0.56 | -0.52 ± 1.03 | -1.09 ± 0.65 | -0.16 ± 0.75 |
| Week 4 visit | -0.28 ± 0.42 | -0.69 ± 0.76 | -0.86 ± 0.63 | -0.68 ± 1.32 | -0.33 ± 0.69 |
| Week 8 Visit | -0.28 ± 0.60 | -0.92 ± 0.60 | -0.89 ± 0.68 | -1.03 ± 1.12 | -0.09 ± 0.82 |
| Week 12 visit | -0.26 ± 0.48 | -0.72 ± 1.03 | -0.86 ± 0.61 | -0.87 ± 1.24 | -0.29 ± 0.73 |
| End-of-treatment visit | -0.26 ± 0.48 | -0.72 ± 1.03 | -0.86 ± 0.61 | -0.87 ± 1.24 | -0.30 ± 0.71 |
The change was defined as: Total lymphocyte count at end-of-treatment (EOT) minus total lymphocyte count at baseline. A negative change over time indicates that the number of peripheral circulating lymphocytes has decreased. The value at baseline was defined as the last non-missing value obtained from a sample taken prior to the first study treatment intake. End-of-treatment (EOT) was defined as the last post-baseline value with treatment for at least 21 days up to Week 12. The modified pharmacodynamics analysis set includes all participants who: * received at least 21 days of study treatment \& * with lymphocyte count measurements at baseline and post-baseline (namely, one sample taken at least 21 days after the first study treatment intake and no later than 7 days after the last study treatment intake with no treatment interruption documented in the first 21 days) \& * with cenerimod plasma concentrations at Week 4 consistent with expectations.
| 10^9 cells/L | Cenerimod 0.5 mg (Part A) | Cenerimod 1 mg (Part A) | Cenerimod 2 mg (Part A) | Cenerimod 4 mg (Part B) | Matching Placebo |
|---|---|---|---|---|---|
| Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT) Based on Pharmacokinetic Cthrough Profiles | -0.26 ± 0.48 | -0.96 ± 0.68 | -0.86 ± 0.61 | -1.48 ± 0.73 | -0.32 ± 0.72 |
The primary objective of the clinical study was to see whether cenerimod could reduce the number of circulating lymphocytes in the bloodstream of people with systemic lupus erythematosus (SLE). The reduction of the total lymphocyte count over a treatment period indicates a pharmacodynamic effect. The modified pharmacodynamics analysis set includes all participants who: * received at least 21 days of study treatment \& * with lymphocyte count measurements at baseline and post-baseline (namely, one sample taken at least 21 days after the first study treatment intake and no later than 7 days after the last study treatment intake with no treatment interruption documented in the first 21 days) \& * with cenerimod plasma concentrations at Week 4 consistent with expectations.
| 10^9 cells/L | Cenerimod 0.5 mg (Part A) | Cenerimod 1 mg (Part A) | Cenerimod 2 mg (Part A) | Cenerimod 4 mg (Part B) | Matching Placebo |
|---|---|---|---|---|---|
| Baseline visit | 1.37 ± 0.52 | 1.83 ± 0.79 | 1.62 ± 0.75 | 2.04 ± 0.80 | 1.66 ± 0.91 |
| Week 2 visit | 1.24 ± 0.34 | 1.38 ± 0.49 | 1.19 ± 0.89 | 0.79 ± 0.44 | 1.44 ± 0.44 |
| Week 4 visit | 1.09 ± 0.27 | 0.99 ± 0.38 | 0.73 ± 0.39 | 0.71 ± 0.49 | 1.31 ± 0.5 |
| Week 8 visit | 1.08 ± 0.43 | 0.91 ± 0.40 | 0.73 ± 0.36 | 0.51 ± 0.28 | 1.49 ± 0.73 |
| Week 12 visit | 1.11 ± 0.37 | 0.87 ± 0.34 | 0.76 ± 0.44 | 0.57 ± 0.21 | 1.33 ± 0.54 |
| End-of-treatment visit | 1.11 ± 0.37 | 0.87 ± 0.34 | 0.76 ± 0.44 | 0.57 ± 0.21 | 1.34 ± 0.51 |
| End-of-study visit | 1.42 ± 0.37 | 1.42 ± 0.58 | 1.35 ± 0.45 | 1.14 ± 0.52 | 1.71 ± 0.86 |
Percentage change in total lymphocyte count from baseline to end-of-treatment (EOT). Percent change from baseline is defined as the absolute change from baseline divided by the baseline value (if the baseline value is \> 0) and then multiplied by 100. A negative change over time indicates that the number of peripheral circulating lymphocytes has decreased. The reduction of the total lymphocyte count over a treatment period indicates a pharmacodynamic effect. The modified pharmacodynamics analysis set includes all participants who: * received at least 21 days of study treatment \& * with lymphocyte count measurements at baseline and post-baseline (namely, one sample taken at least 21 days after the first study treatment intake and no later than 7 days after the last study treatment intake with no treatment interruption documented in the first 21 days) \& * with cenerimod plasma concentrations at Week 4 consistent with expectations.
| Percent change of total lymphocyte count | Cenerimod 0.5 mg (Part A) | Cenerimod 1 mg (Part A) | Cenerimod 2 mg (Part A) | Cenerimod 4 mg (Part B) | Matching Placebo |
|---|---|---|---|---|---|
| Total Lymphocyte Count Percent Change From Baseline to End-of-treatment (EOT) | -12.23 ± 34.29 | -47.76 ± 20.37 | -51.52 ± 22.53 | -69.27 ± 13.68 | -5.04 ± 39.22 |
Collected over All Adverse Events and Serious Adverse Events that occurred after the intake of the first study treatment and up to 6 weeks after study treatment discontinuation are reported, assessed up to 18 weeks.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cenerimod 0.5 mg | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Cenerimod 1 mg | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Cenerimod 2 mg | 0/13 (0%) | 0/13 (0%) | 6/13 (46.2%) |
| Cenerimod 4 mg | 0/13 (0%) | 0/13 (0%) | 5/13 (38.5%) |
| Matching Placebo | 0/17 (0%) | 1/17 (5.9%) | 9/17 (52.9%) |
| Event | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 4 mg | Matching Placebo |
|---|---|---|---|---|---|
| Pancreatitis chronicGastrointestinal disorders | 0/12 | 0/12 | 0/13 | 0/13 | 1/17 |
| Cholecystitis chronicHepatobiliary disorders | 0/12 | 0/12 | 0/13 | 0/13 | 1/17 |
| Post cholecystectomy syndromeHepatobiliary disorders | 0/12 | 0/12 | 0/13 | 0/13 | 1/17 |
| Event | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 4 mg | Matching Placebo |
|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 2/12 | 0/12 | 0/13 | 0/13 | 1/17 |
| Alanine aminotransferase increasedInvestigations | 2/12 | 0/12 | 0/13 | 0/13 | 0/17 |
| HeadacheNervous system disorders | 2/12 | 0/12 | 0/13 | 0/13 | 1/17 |
| NasopharyngitisInfections and infestations | 0/12 | 0/12 | 0/13 | 1/13 | 2/17 |
| LymphopeniaBlood and lymphatic system disorders | 0/12 | 1/12 | 1/13 | 0/13 | 0/17 |
| Abdominal discomfortGastrointestinal disorders | 1/12 | 0/12 | 0/13 | 0/13 | 0/17 |
| GastroduodenitisGastrointestinal disorders | 0/12 | 1/12 | 0/13 | 0/13 | 0/17 |
| NauseaGastrointestinal disorders | 1/12 | 1/12 | 0/13 | 0/13 | 0/17 |
| Respiratory tract infection viralInfections and infestations | 0/12 | 1/12 | 0/13 | 0/13 | 1/17 |
| Aspartate aminotransferase increasedInvestigations | 1/12 | 0/12 | 0/13 | 0/13 | 0/17 |
Full analysis set (N=67). Pharmacodynamic analysis set (PD set, N=64) at least 21 days of treatment, with lymphocyte count measurements at baseline and post-baseline. Modified pharmacodynamic analysis set (N=60) excluded 4 patients from PD set with low, or below the lower limit of quantification (BLQ) Ctrough levels.
| Age, Continuous(years) | Cenerimod 0.5 mg (Part A) | Cenerimod 1 mg (Part A) | Cenerimod 2 mg (Part A) | Cenerimod 4 mg (Part B) | Matching Placebo (Part A and Part B) | Total |
|---|---|---|---|---|---|---|
| Full analysis set | 41.4 ± 13.2 | 37.0 ± 6.4 | 39.2 ± 11.8 | 41.7 ± 8.1 | 41.0 ± 9.5 | 40.1 ± 9.9 |
| Pharmacodynamic analysis set | 41.4 ± 13.2 | 38.1 ± 5.4 | 39.2 ± 11.8 | 41.7 ± 8.1 | 41.8 ± 9.2 | 40.6 ± 9.8 |
| Modified pharmacodynamics analysis set | 41.4 ± 13.2 | 38.1 ± 5.4 | 39.2 ± 11.8 | 41.9 ± 8.6 | 41.8 ± 9.2 | 40.6 ± 9.9 |
| Sex: Female, Male(Participants) | Cenerimod 0.5 mg (Part A) | Cenerimod 1 mg (Part A) | Cenerimod 2 mg (Part A) | Cenerimod 4 mg (Part B) | Matching Placebo (Part A and Part B) | Total |
|---|---|---|---|---|---|---|
| Full analysis set — Female | 11 | 12 | 12 | 10 | 16 | 61 |
| Full analysis set — Male | 1 | 0 | 1 | 3 | 1 | 6 |
| Pharmacodynamic analysis set — Female | 11 | 10 | 12 | 10 | 16 | 59 |
| Pharmacodynamic analysis set — Male | 1 | 0 | 1 | 3 | 0 | 5 |
| Modified pharmacodynamic analysis set — Female | 11 | 10 | 12 | 7 | 16 | 56 |
| Modified pharmacodynamic analysis set — Male | 1 | 0 | 1 | 2 | 0 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Cenerimod 0.5 mg (Part A) | Cenerimod 1 mg (Part A) | Cenerimod 2 mg (Part A) | Cenerimod 4 mg (Part B) | Matching Placebo (Part A and Part B) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 12 | 12 | 13 | 13 | 17 | 67 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cenerimod 0.5 mg (Part A) | Cenerimod 1 mg (Part A) | Cenerimod 2 mg (Part A) | Cenerimod 4 mg (Part B) | Matching Placebo (Part A and Part B) | Total |
|---|---|---|---|---|---|---|
| Full analysis set — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Full analysis set — Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Full analysis set — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Full analysis set — Black or African American | 0 | 0 | 0 | 0 | 2 | 2 |
| Full analysis set — White | 12 | 12 | 13 | 13 | 15 | 65 |
| Full analysis set — More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Full analysis set — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Pharmacodynamic analysis set — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Pharmacodynamic analysis set — Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Pharmacodynamic analysis set — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Pharmacodynamic analysis set — Black or African American | 0 | 0 | 0 | 0 | 2 | 2 |
| Pharmacodynamic analysis set — White | 12 | 10 | 13 | 13 | 14 | 62 |
| Pharmacodynamic analysis set — More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Pharmacodynamic analysis set — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Modified pharmacodynamic analysis set — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Modified pharmacodynamic analysis set — Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Modified pharmacodynamic analysis set — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Modified pharmacodynamic analysis set — Black or African American | 0 | 0 | 0 | 0 | 2 | 2 |
| Modified pharmacodynamic analysis set — White | 12 | 10 | 13 | 9 | 14 | 58 |
| Modified pharmacodynamic analysis set — More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Modified pharmacodynamic analysis set — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cenerimod 0.5 mg (Part A) | Cenerimod 1 mg (Part A) | Cenerimod 2 mg (Part A) | Cenerimod 4 mg (Part B) | Matching Placebo (Part A and Part B) | Total |
|---|---|---|---|---|---|---|
| United States | 1 | 1 | 0 | 0 | 2 | 4 |
| Ukraine | 3 | 1 | 2 | 1 | 2 | 9 |
| Georgia | 2 | 1 | 1 | 1 | 1 | 6 |
| Belarus | 0 | 1 | 2 | 2 | 2 | 7 |
| Bulgaria | 3 | 2 | 2 | 7 | 5 | 19 |
| Russia | 3 | 6 | 6 | 2 | 5 | 22 |
| Body mass index(kg/m^2) | Cenerimod 0.5 mg (Part A) | Cenerimod 1 mg (Part A) | Cenerimod 2 mg (Part A) | Cenerimod 4 mg (Part B) | Matching Placebo (Part A and Part B) | Total |
|---|---|---|---|---|---|---|
| Full analysis set | 25.2 ± 5.1 | 27.4 ± 8.0 | 26.0 ± 5.1 | 27.5 ± 4.7 | 25.4 ± 6.8 | 26.3 ± 6.0 |
| Pharmacodynamic analysis set | 25.2 ± 5.1 | 28.8 ± 8.1 | 26.0 ± 5.1 | 27.5 ± 4.7 | 25.5 ± 7.0 | 26.5 ± 6.1 |
| Modified pharmacodynamic analysis set | 25.2 ± 5.1 | 28.8 ± 8.1 | 26.0 ± 5.1 | 28.3 ± 5.4 | 25.5 ± 7.0 | 26.5 ± 6.2 |
| Disease history time from first Systemic Lupus Erythematosus symptoms(years) | Cenerimod 0.5 mg (Part A) | Cenerimod 1 mg (Part A) | Cenerimod 2 mg (Part A) | Cenerimod 4 mg (Part B) | Matching Placebo (Part A and Part B) | Total |
|---|---|---|---|---|---|---|
| Full analysis set | 3.7 (1.6 to 23.7) | 8.2 (0.6 to 22.5) | 6.7 (1.4 to 20.9) | 4.6 (0.8 to 10.5) | 7.9 (1.1 to 22.1) | 6.0 (0.6 to 23.7) |
| Pharmacodynamic analysis set | 3.7 (1.6 to 23.7) | 9.2 (0.6 to 22.5) | 6.7 (1.4 to 20.9) | 4.6 (0.8 to 10.5) | 7.9 (1.7 to 22.1) | 6.2 (0.6 to 23.7) |
| Modified pharmacodynamic analysis set | 3.7 (1.6 to 23.7) | 9.2 (0.6 to 22.5) | 6.7 (1.4 to 20.9) | 3.2 (0.8 to 6.7) | 7.9 (1.7 to 22.1) | 6.2 (0.6 to 23.7) |
| Time from first Systemic Lupus Erythematosus diagnosis(years) | Cenerimod 0.5 mg (Part A) | Cenerimod 1 mg (Part A) | Cenerimod 2 mg (Part A) | Cenerimod 4 mg (Part B) | Matching Placebo (Part A and Part B) | Total |
|---|---|---|---|---|---|---|
| Full analysis set | 2.4 (1.4 to 23.7) | 6.2 (0.5 to 22.3) | 4.5 (1.3 to 17.0) | 2.9 (0.6 to 9.2) | 4.9 (0.5 to 21.4) | 3.8 (0.5 to 23.7) |
| Pharmacodynamic analysis set | 2.4 (1.4 to 23.7) | 5.8 (0.5 to 22.3) | 4.5 (1.3 to 17.0) | 2.9 (0.6 to 9.2) | 5.0 (0.5 to 21.4) | 3.6 (0.5 to 23.7) |
| Modified pharmacodynamic analysis set | 2.4 (1.4 to 23.7) | 5.8 (0.5 to 22.3) | 4.5 (1.3 to 17.0) | 1.3 (0.6 to 5.2) | 5.0 (0.5 to 21.4) | 3.6 (0.5 to 23.7) |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2015 to primary completion in Jan 2017, 19 months.
Results were first posted in Feb 2020, 3 years 1 month after primary completion. A results delay was requested in Feb 2018.
Of 37 phase 1/2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cenerimod
Lupus Erythematosus, Systemic →